Results 251 to 260 of about 86,128 (305)

Age at First Pregnancy, Adult Weight Gain and Postmenopausal Breast Cancer Risk: The PROCAS Study (United Kingdom)

International Journal of Cancer, EarlyView.
An early first pregnancy is protective against postmenopausal breast cancer. However, pregnancy is also a key contributor to weight gain, and adult weight gain increases postmenopausal breast cancer risk. This prospective cohort study quantified the combined effect of adult weight gain and age at first pregnancy on postmenopausal breast cancer risk ...
Lee Malcomson, Adam Brentnall, Andrew G. Renehan, Mary Pegington, Elaine F. Harkness, Jake Southworth, D. Gareth Evans, Michelle Harvie   +7 more
wiley   +1 more source

Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long‐Term Follow‐Up From the CAP Randomised Trial

International Journal of Cancer, EarlyView.
Uncertainty persists over whether the benefits of prostate‐specific antigen (PSA) screening outweigh harms from overdiagnosis, a key barrier to population‐wide adoption. Here, English male mortality rates were analyzed alongside long‐term data from the UK Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) to estimate age‐specific ...
Adam R. Brentnall, Matejka Rebolj, Peter Sasieni, Garth Funston, Rhian Gabe, Andrew J. Vickers   +5 more
wiley   +1 more source

Health Care Policy Implementation Trial of Primary Human Papillomavirus–Based Cervical Screening in Denmark

International Journal of Cancer, EarlyView.
Uncertainty has persisted over whether human papillomavirus (HPV) testing outperforms high‐quality cytology in real‐world cervical cancer screening programs. To address this, Denmark launched a nationwide trial in 2021, implementing an HPV‐based screening strategy using specialized algorithms integrated with molecular and cytology triage to optimize ...
Jesper Bonde, Jeppe Bennekou Schroll, Birgitte Tønnes Pedersen, Elsebeth Lynge, Marianne Waldstrøm, Petra Hall Viborg, Anna Frandsen, Rikke Holst Andersen, Susanne Nielsen, Doris Schledermann, Bettina Kjær Kristensen, Berit Andersen, on behalf of the National Danish Cervical Cancer Screening Steering Committee   +12 more
wiley   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, EarlyView.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Estimation of the bivariate distribution function for interval censored data [comunicação oral]

Gustavo Soutinho, Marta Azevedo, Luís Meira-Machado   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bayesian transformation models with partly interval‐censored data

Statistics in Medicine, 2021
In many scientific fields, partly interval‐censored data, which consist of exactly observed and interval‐censored observations on the failure time of interest, appear frequently. However, methodological developments in the analysis of partly interval‐censored data are relatively limited and have mainly focused on additive or proportional hazards models.
Chunjie Wang, Jingjing Jiang, Xinyuan Song   +2 more
openaire   +3 more sources

Regression with Interval-Censored Data

Biometrika, 1995
Summary: Interval-censored data result when survival times are not known exactly, but are only known to have occurred between intermittent examination times. Here the accelerated failure time model is treated for interval- censored data. A class of score statistics that may be used for estimation and confidence procedures is proposed.
Rabinowitz, Daniel, Tsiatis, Anastasios, Aragon, Jorge   +2 more
openaire   +1 more source

Hazard Regression with Interval-Censored Data

Biometrics, 1997
In a recent paper, Kooperberg, Stone, and Truong (1995a) introduced hazard regression (HARE), in which linear splines and their tensor products are used to estimate the conditional log-hazard function based on possibly censored, positive response data and one or more covariates.
Kooperberg, Charles, Clarkson, Douglas B.   +1 more
openaire   +3 more sources

Restricted mean survival time for interval‐censored data

Statistics in Medicine, 2020
Restricted mean survival time (RMST) evaluates the mean event‐free survival time up to a prespecified time point. It has been used as an alternative measure of treatment effect owing to its model‐free structure and clinically meaningful interpretation of treatment benefit for right‐censored data.
Chenyang Zhang, Yuanshan Wu, Guosheng Yin   +2 more
openaire   +2 more sources